摘要
目的:探讨尿生存素(survivin)检测在膀胱肿瘤诊断中的价值。方法:收集膀胱癌患者47例,泌尿系统非尿路上皮肿瘤22例,泌尿系非肿瘤患者9例,健康志愿者8例的尿液。ELISA法检测尿中survivin浓度,并用半定量RT-PCR和Western-blot方法验证其检测结果的准确性。结果:以1ng/ml为限,膀胱癌组尿survivin测定结果和其他各组相比阳性率明显增高,χ2检验结果显示差异有统计学意义(P<0.05)。半定量RT-PCR和Western-blot结果证明检测结果的准确性较高。结论:尿survivin浓度的ELISA方法检测可能是一种敏感性高、特异性强、无创、简便的膀胱癌群体筛查和术后随访的检查方法。
Objective：To investigate the potential suitability of survivin detection in urine as a novel predictive/ prognostic molecular marker of bladder cancer. Methods：Survey of urine specimens from 4 groups：healthy volunteers （n= 8） and patients with nonneoplastic urinary tract disease （n = 9）, other genitourinary cancer （n = 22）, new-onset or recurrent bladder cancer（n= 47）. Survivin levels, analyzed by ELISA detection system and confirmed by reverse transcriptase polymerase chainreaction （RT-PCR） and Western blot, in urine samples of the 4 participant groups. Results：Survivin was detected in the urine samples of the patients with bladder cancer. Survivin was not detected in the urine samples of patients without bladder cancer （P〈0. 05）. ELISA detection outcomes were confirmed by RT-PCR and Western blot. Conclusions： Highly sensitive and specific determination of urine survivin appears to provide a simple, noninvasive diagnostic test to identify patients with new or recurrent bladder cancer.
出处
《临床泌尿外科杂志》
2007年第11期838-840,共3页
Journal of Clinical Urology
基金
常州市武进区科技局资助项目(NO2005-7-7)
关键词
尿
生存素
膀胱癌
Urine
Survivin
Bladder cancer
